LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Condense Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Sender:
Lactation Information and Discussion <[log in to unmask]>
Date:
Sun, 8 Dec 2013 06:20:41 -0600
MIME-version:
1.0
Reply-To:
Lactation Information and Discussion <[log in to unmask]>
Content-type:
text/plain; charset=UTF-8
Subject:
From:
Pat Young <[log in to unmask]>
Message-ID:
<18351338.1067533.1386505241439.JavaMail.root@vznit170146>
Content-transfer-encoding:
7bit
Parts/Attachments:
text/plain (17 lines)
Hale says L2 and American College of Radiology concludes that it is safe for mother-infant dyad to continue breastfeeding after the administration of a gadolinium-containing contrast medium.  One study that he sites says "that the very small an]mount of gadopentrate dimeglumine transferred to the nursing infant does not warrant the potentially traumatic 24 hour suspension of breastfeeding for lactating women..."   
 
I also looked in Lactmed (NIH) and the first ref said that the infant receives less than 1% of a dose that would be actually used on that infant, if the infant was having the study.
 
I guess if mom is still apprehensive, she could call the infant Risk Center.  I'd say no worries, I trust 2012 Hale  Pat in SNJ

             ***********************************************

Archives: http://community.lsoft.com/archives/LACTNET.html
To reach list owners: [log in to unmask]
Mail all list management commands to: [log in to unmask]
COMMANDS:
1. To temporarily stop your subscription write in the body of an email: set lactnet nomail
2. To start it again: set lactnet mail
3. To unsubscribe: unsubscribe lactnet
4. To get a comprehensive list of rules and directions: get lactnet welcome

ATOM RSS1 RSS2